About belzutifan
HIF-2α inhibitor
Used for
- Treats certain kidney cancers, von Hippel-Lindau disease-related tumors, and advanced pheochromocytoma or paraganglioma.
Usual adult dose
Usually 120 mg by mouth once daily; dosing may be reduced for side effects.
Common side effects
- Low red blood cells (anemia)
- Tiredness
- Headache
- Dizziness
Important warnings
- Can cause severe anemia and low blood oxygen; monitoring is required.
- May harm an unborn baby; pregnancy testing and effective contraception are required.
- Can reduce hormonal contraceptive effectiveness; use non-hormonal contraception during treatment and afterward.
- May cause dangerously low blood sugar, especially with certain tumors.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for one week after the last dose.
Breastfeeding
Do not breastfeed during treatment or for one week after the last dose.
Interactions
- May lower levels of hormonal contraceptives and some medicines, including CYP3A substrates.
- Strong CYP2C19 or CYP3A inhibitors can increase belzutifan exposure.
- Strong or moderate CYP3A inducers can reduce belzutifan exposure.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.